Carregando...
Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
BACKGROUND: Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier compared with previous EGFR-TKIs, and thus, a 52% reduction in the risk of intracranial disease progression is seen when...
Na minha lista:
| Publicado no: | Neurooncol Adv |
|---|---|
| Principais autores: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7648590/ https://ncbi.nlm.nih.gov/pubmed/33196042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa125 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|